MedTrace Logo

Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer

NCT04774380 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2025-05-23

Study results available
· View outcomes & findings →

Summary

Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer.

Conditions

  • Extensive-stage Small Cell Lung Cancer

Interventions

DRUG

Durvalumab

Participants will receive durvalumab via IV infusion on Day 1 of each cycle.

DRUG

Cisplatin

Participants will receive cisplatin via IV administration on Day 1 of each cycle.

DRUG

Carboplatin

Participants will receive carboplatin via IV administration Day 1 of each cycle.

DRUG

Etoposide

Participants will receive etoposide via IV administration on days 1 to 3 of each cycle.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-11
Primary Completion
2023-06-12
Completion
2025-01-02
FDA Drug
Yes

Countries

  • Bulgaria
  • Canada
  • Czechia
  • Germany
  • Italy
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04774380 on ClinicalTrials.gov